This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Ron Cooper

Chief Executive Officer (CEO)

US$6.0m

Compensación total

Porcentaje del salario del CEO	9.8%
Permanencia del CEO	7.7yrs
Participación del CEO	0.2%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ron Cooper en comparación con los beneficios de Albireo Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2022	n/a	n/a	-US$131m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$6m	US$590k	-US$34m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$136m
Mar 31 2021	n/a	n/a	-US$120m
Dec 31 2020	US$3m	US$570k	-US$108m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$78m
Dec 31 2019	US$3m	US$551k	-US$63m
Sep 30 2019	n/a	n/a	-US$71m
Jun 30 2019	n/a	n/a	-US$63m
Mar 31 2019	n/a	n/a	-US$61m
Dec 31 2018	US$4m	US$530k	-US$46m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$2m	US$460k	-US$24m
Sep 30 2017	n/a	n/a	-US$31m
Jun 30 2017	n/a	n/a	-US$28m
Mar 31 2017	n/a	n/a	-US$20m
Dec 31 2016	US$4m	US$400k	-US$16m

Compensación vs. Mercado: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the German market ($USD1.12M).

Compensación vs. Ingresos: Ron's compensation has increased whilst the company is unprofitable.

CEO

Ron Cooper (59 yo)

7.7yrs

Permanencia

US$6,041,334

Compensación

Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ronald H. Cooper	CEO, President & Director	7.7yrs	US$6.04m	0.16% $ 1.4m
Simon Nicolas Harford	CFO & Treasurer	4.4yrs	US$1.71m	0.066% $ 572.3k
Martha Carter	Chief Regulatory Officer	6.3yrs	US$1.73m	0.018% $ 152.3k
Per-Goran Gillberg	Co-Founder & VP of Development	no data	sin datos	sin datos
Jan Mattsson	Chief Scientific Officer	15.2yrs	US$1.40m	0.17% $ 1.5m
Joan Connolly	Chief Technology Officer	1.9yrs	sin datos	sin datos
Jason Duncan	Chief Legal Officer	4.8yrs	sin datos	0.016% $ 137.3k
Michelle Graham	Chief Human Resources Officer	3.3yrs	sin datos	0.027% $ 230.9k
Kristina Torfgard	VP & Global Project Head	no data	sin datos	sin datos
Pamela Stephenson	Chief Commercial Officer	4yrs	US$1.96m	0.11% $ 926.5k
Constantine Chinoporos	Chief Business Officer	1.3yrs	sin datos	sin datos
Paul Streck	Chief Medical Officer	less than a year	sin datos	sin datos

4.2yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: BDQM's management team is considered experienced (4.2 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ronald H. Cooper	CEO, President & Director	7.5yrs	US$6.04m	0.16% $ 1.4m
David Chiswell	Independent Chairman of the Board	15.1yrs	US$282.44k	0.27% $ 2.3m
Davey Scoon	Independent Director	6.3yrs	US$266.82k	0.14% $ 1.3m
Michael Gutch	Independent Director	7.4yrs	US$264.94k	0.13% $ 1.1m
Craig Hopkinson	Director	less than a year	sin datos	sin datos
Habib Dable	Independent Director	less than a year	sin datos	sin datos
Stephanie Okey	Independent Director	4.8yrs	US$249.94k	0.14% $ 1.2m
Susan Alesina	Director	less than a year	sin datos	sin datos

5.5yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: BDQM's board of directors are considered experienced (5.5 years average tenure).

This company listing is no longer active

Albireo Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Albireo Pharma, Inc. Announces New Committee Member Appointments

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Insufficient new directors

Albireo Pharma, Inc., Annual General Meeting, Jun 16, 2022

Recent updates

Forecast to breakeven in 2025

Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Third quarter 2022 earnings released: US$1.92 loss per share (vs US$2.96 profit in 3Q 2021)

Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liver Diseases

Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

Albireo Pharma, Inc. to Present Late Breaking Bylvay (odevixibat) Data at AASLD 2022

Albireo Pharma, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® (Odevixibat) in Alagille Syndrome

Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

No longer forecast to breakeven

Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of All Types of Progressive Familial Intrahepatic Cholestasis Patients in Italy

Albireo Pharma, Inc. Announces New Committee Member Appointments

Second quarter 2022 earnings released: US$2.04 loss per share (vs US$1.90 loss in 2Q 2021)

No longer forecast to breakeven

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Albireo Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Albireo Pharma, Inc. Announces Lancet Gastroenterology & Hepatology Published the Results of the Pivotal PEDFIC 1 Trial

Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from Russell Microcap Value Index

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

Albireo Pharma, Inc. Announces Presentation of New Data in Pediatric and Adult Liver Diseases

Albireo Pharma, Inc. Provides Sales Guidance for the Year 2022

First quarter 2022 earnings released: US$2.19 loss per share (vs US$2.29 loss in 1Q 2021)

Albireo Pharma, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Albireo Pharma, Inc., Annual General Meeting, Jun 16, 2022

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Albireo Pharma, Inc. Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

Forecast to breakeven in 2024

Albireo Announces Positive Topline Data from Phase 1 Study of A3907

Albireo Pharma, Inc. Presenting New Bylvay™ (Odevixibat) Data at NASPGHAN 2021

Third quarter 2021 earnings released: EPS US$2.96 (vs US$1.96 loss in 3Q 2020)

Albireo Pharma, Inc. Receives UK MHRA Approval of Bylvay® (odevixibat)

Second quarter 2021 earnings released: US$1.90 loss per share (vs US$1.38 loss in 2Q 2020)

Albireo Pharma, Inc. Announces European Commission Authorization of Bylvay (Odevixibat), the First Drug Approved for the Treatment of All Subtypes of Progressive Familial Intrahepatic Cholestasis

Albireo Pharma, Inc. Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming Easl International Liver Congress

Albireo Pharma, Inc Presents Clinical Data from Its Phase 3 Pedfic 1 Study and an Interim Data Cut of the Pedfic 2 Long-Term Extension Study of Its Lead Product Candidate, Bylvay

Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Albireo Pharma, Inc. Announces the Presentation of New Data from its Phase 3 PEDFIC 1 Study and PEDFIC 2 Long-Term Extension Study of its Lead Product Candidate, Bylvay

First quarter 2021 earnings released: US$2.29 loss per share (vs US$2.23 loss in 1Q 2020)

New 90-day low: €27.62

Full year 2020 earnings released: US$6.73 loss per share (vs US$5.04 loss in FY 2019)

Revenue beats expectations

Albireo Pharma, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €34.76

Albireo Announces U.S. Fda Acceptance of New Drug Application for Odevixibat

Albireo Pharma, Inc. Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome

New 90-day high: €33.98

Albireo Pharma, Inc. Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC

Albireo Pharma, Inc. Announce New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease

Third quarter 2020 earnings released: US$1.96 loss per share

Revenue beats expectations

Albireo Pharma, Inc.’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers

Albireo Pharma, Inc. to Report Q3, 2019 Results on Nov 06, 2019

Albireo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $160 million.

New 90-day high - €33.14

New 90-day low - €20.02

Albireo Pharma, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media